BIOCRATES Life Sciences AG and Selexis SA join forces to further optimize high-yield mammalian cell cultures
01-Sep-2010 -
BIOCRATES Life Sciences AG and Selexis SA have entered into a co-development agreement to further increase drug substance yields from mammalian cell cultures. Because most protein therapeutics require specific post-translational modifications (e.g., glycosylation) to exert their full therapeutic ...
cell cultures
Glycosylation
recombinant proteins
+1